RE:New Press Release - Evome Medical Technologies Posts Third Quarter 2024 Results, Generates $424,000 in Adjusted EBITDA on Stable Revenues, Further Reduces DebtPretty much as expected, I think. There continues to be slight improvements on cost containment, which is nice to see. We won't see Q4 results for 5 months so what management is able to get in return for selling DaMar will be the next big catalyst determining where the share price will be heading.